920 results on '"Marshall, John L"'
Search Results
2. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer
3. Tumor specimen cold ischemia time impacts molecular cancer drug target discovery
4. Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer
5. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
6. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study
7. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets
8. Our Board Members Have Been Busy! Take a look to see what they've been up to
9. The current state of molecular profiling in gastrointestinal malignancies
10. Systemic Therapy for Colorectal Cancer Liver Metastases: Sorting Through the Options
11. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer
12. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
13. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer
14. Metastatic Colorectal Cancer
15. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
16. Molecular profile of BRCA-mutated biliary tract cancers
17. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients
18. Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes
19. CEA
20. Neoadjuvant Chemoradiotherapy and Neoadjuvant Chemotherapy
21. Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic
22. Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer
23. Phase I Study of Hypofractionated Proton Beam Radiotherapy in Adjuvant Pancreatic Cancer (PROTON-PANC)
24. Systemic Therapy for Colorectal Cancer Liver Metastases: Sorting Through the Options
25. Epidermal Growth Factor Inhibitors
26. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer
27. A Silver-Free, Single-Sheet Imaging Medium Based on Acid Amplification
28. Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC)
29. Molecular Profiling and the Promise of Precision Medicine: 'You can't miss these opportunities. They don't come every day.'
30. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
31. Molecular Variances Between Right- and Left-sided Colon Cancers
32. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies
33. Supplementary Table S2 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
34. Data from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
35. Figure S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
36. Supplementary appendix from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
37. Supplemental Figure 1 from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
38. Table S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
39. Supplementary Figure Legend from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
40. Data from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
41. Supplementary Data from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
42. Supplementary Figure from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
43. Supplementary Table from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
44. Data from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
45. Figure S5 from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
46. Supplementary Methods from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
47. Supplementary Table S3 from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer
48. Supplementary Table 1 from A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
49. Figure S2 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
50. Supplementary Table S2 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.